You are here:

1. Homepage
2. Pharmacovigilance
3. Information on Risks

Rosiglitazone: The BfArM and the EMA emphasise restrictions in indications

In July 2010 the CHMP at the EMA initiated assessment of new study results on the antidiabetic, rosiglitazone. The BfArM, like the CHMP, is repeating the advice that the long-existing restrictions in rosiglitazone indications should be strictly observed by prescribing physicians.

information - full text (available in German only)